LING Bofan, JIANG Yuqi, HOU Qian, SHI Zheng, JIN Zhichao. Mechanism of Jianpi Huayu Decoction in improving blood hypercoagulability of patients with advanced gastric cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 96-101, 105. DOI: 10.7619/jcmp.20211647
Citation: LING Bofan, JIANG Yuqi, HOU Qian, SHI Zheng, JIN Zhichao. Mechanism of Jianpi Huayu Decoction in improving blood hypercoagulability of patients with advanced gastric cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 96-101, 105. DOI: 10.7619/jcmp.20211647

Mechanism of Jianpi Huayu Decoction in improving blood hypercoagulability of patients with advanced gastric cancer

More Information
  • Received Date: April 18, 2021
  • Available Online: July 07, 2021
  • Published Date: July 14, 2021
  •   Objective  To observe the effect of Jianpi Huayu Decoction on coagulation indexes, tissue factor (TF), inflammation indexes and platelet aggregation test in stages Ⅲ to Ⅳ gastric cancer patients with blood hypercoagulability.
      Methods  Totally 50 patients were randomly divided into experimental group (n=25) and control group (n=25). The experimental group received Jianpi Huayu Decoction combined with basic treatment for tumor, while the control group only received basic treatment for tumor, and both groups were treated for (42±2) days. On the 1st day, the (21±2) day and (42±2) day, the subjects were interviewed and the results were statistically analyzed.
      Results  ① After 2 cycles of treatment, the levels of D-Dimer (D-D) and fibrinogen (FIB) in the experimental group were significantly lower than those in the control group, while the thrombin time (TT) was significantly longer than that in the control group (P < 0.01). ② After treatment, tissue factor (TF) in the experimental group was significantly lower than that in the control group (P < 0.01). ③ Level of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the experimental group were significantly lower than those in the control group (P < 0.01). ④ FIB was positively correlated with TF (r=0.447, P < 0.01), and the changes after treatment also showed a significant positive correlation between two indexes (r=0.434, P < 0.05). ⑤ There was a significant positive correlation between FIB and IL-1β (r=0.357, P < 0.05), and the changes after treatment also showed a significant positive correlation between two indexes (r=0.555, P < 0.05).
      Conclusion  Jianpi Huayu Decoction can improve the blood hypercoagulability in patients with advanced gastric cancer by reducing the expressions of TF and IL-1β.
  • [1]
    PALTA S, SAROA R, PALTA A. Overview of the coagulation system[J]. Indian J Anaesth, 2014, 58(5): 515-523. doi: 10.4103/0019-5049.144643
    [2]
    REPETTO O, DE RE V. Coagulation and fibrinolysis in gastric cancer[J]. Ann N Y Acad Sci, 2017, 1404(1): 27-48. doi: 10.1111/nyas.13454
    [3]
    陈万青, 郑荣寿, 曾红梅, 等. 2011年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2015, 24(1): 1-10. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201501001.htm
    [4]
    TORBICKI A, KONSTANTINIDES S, PERRIER A, et al. Guidelines on the diagnosis and management of acute pulmonary embolism(J(. European Heart Journal, 2008, 8(29): 2276-2315.
    [5]
    GUO Q, JIN Z, YUAN Y, et al. New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy[J]. J Immunol Res, 2016, 2016: 9720912.
    [6]
    YAMASHITA A, ZHAO Y, ZHAO S J, et al. Arterial (18)F-fluorodeoxyglucose uptake reflects balloon catheter-induced Thrombus formation and tissue factor expression via nuclear factor-κB in rabbit atherosclerotic lesions[J]. Circ J, 2013, 77(10): 2626-2635. doi: 10.1253/circj.CJ-12-1463
    [7]
    BORST O, MÜNZER P, SCHMID E, et al. 1, 25(OH)2 vitamin D3-dependent inhibition of platelet Ca2+ signaling and Thrombus formation in klotho-deficient mice[J]. FASEB J, 2014, 28(5): 2108-2119. doi: 10.1096/fj.13-239277
    [8]
    CATTANEO M. The platelet P2 receptors in inflammation[J]. Hamostaseologie, 2015, 35(3): 262-266. doi: 10.5482/HAMO-14-09-0044
    [9]
    SARTORI M T, DELLA PUPPA A, BALLIN A, et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role[J]. Thromb Haemost, 2013, 110(2): 378-385. http://www.ncbi.nlm.nih.gov/pubmed/23803674/
    [10]
    KHORANA A A, AHRENDT S A, RYAN C K, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer[J]. Clin Cancer Res, 2007, 13(10): 2870-2875. doi: 10.1158/1078-0432.CCR-06-2351
    [11]
    卓正平. 益气健脾活血汤联合化疗对中晚期胃癌患者治疗效果和卡氏评分的影响[J]. 基层医学论坛, 2017, 21(2): 212-213. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLT201702063.htm
    [12]
    步许海. 联用化疗与益气健脾活血汤对中晚期胃癌患者进行治疗的效果观察[J]. 当代医药论丛, 2016, 14(5): 16-17. doi: 10.3969/j.issn.2095-7629.2016.05.012
    [13]
    余美剑. 益气健脾活血汤联合化疗方案对中晚期胃癌患者的效果分析[J]. 光明中医, 2016, 31(24): 3646-3647. doi: 10.3969/j.issn.1003-8914.2016.24.050
    [14]
    张奕. 益气健脾活血汤联合化疗方案对中晚期胃癌患者的临床观察[J]. 湖北中医药大学学报, 2014, 16(6): 67-69. doi: 10.3969/j.issn.1008-987x.2014.06.22
    [15]
    中华人民共和国卫生部. 胃癌诊断标准WS316-2010[S]. 北京: 中国标准出版社, 2010: 1-10.
    [16]
    AMIN M B, EDGE S B, GREENE F L, et al. AJCC cancer staging manual[M]. 8th ed. Chigaco: Springer, 2017: 11-31.
    [17]
    马军, 吴一龙, 秦叔逵, 等. 中国肿瘤相关静脉血栓栓塞症预防与治疗专家指南(2015版)[J]. 中国实用内科杂志, 2015, 35(11): 907-920. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201511007.htm
    [18]
    田虎, 田思胜. 恶性肿瘤血液高凝状态的中医药治疗[J]. 中医杂志, 2019, 60(7): 572-575. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201907008.htm
    [19]
    史茜. 健脾化瘀解毒方联合FOLFOX方案治疗晚期胃癌的临床研究[D]. 南京: 南京中医药大学, 2009.
    [20]
    陶肖馨. 健脾化瘀方联合化疗治疗晚期胃癌的临床研究[D]. 南京: 南京中医药大学, 2012.
    [21]
    王瑞平, 徐佳丽, 薛刚, 等. 健脾化瘀方对胃癌细胞SGC-7901凋亡相关基因表达的影响[J]. 四川中医, 2014, 32(1): 73-76. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY201401037.htm
    [22]
    滕钰浩, 唐晓龙, 凌博凡, 等. 健脾化瘀方对胃癌MGC-803细胞侵袭转移相关基因表达的影响[J]. 时珍国医国药, 2015, 26(8): 1866-1868. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY201508026.htm
    [23]
    滕钰浩, 凌博凡, 朱云涛, 等. 健脾化瘀方对裸鼠RECK、STAT3等侵袭转移相关基因的影响[J]. 时珍国医国药, 2015, 26(11): 2622-2624. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY201511021.htm
    [24]
    霍苏, 崔鹤蓉, 田学浩, 等. 丹参抑制血小板聚集成分的构效关系及协同作用[J]. 西北药学杂志, 2021, 36(1): 95-100.
    [25]
    周曙光, 韦洁, 廖欣, 等. 基于网络药理学探讨莪术抗血栓作用机制[J]. 中成药, 2020, 42(4): 1062-1065. doi: 10.3969/j.issn.1001-1528.2020.04.047
    [26]
    宋卓. 扶正解毒方对荷瘤小鼠肿瘤相关巨噬细胞介导下血管重塑的调控研究[D]. 北京: 中国中医科学院, 2016.
    [27]
    贾程辉. 扶正解毒方对移植性前胃癌小鼠术后复发模型肿瘤相关巨噬细胞的调控作用研究[D]. 北京: 北京中医药大学, 2014.
    [28]
    黎金华, 田菲, 邱崇笙, 等. 扶正散结方调控lewis肺癌小鼠TAMs免疫重塑作用的相关研究[J]. 中国中药杂志, 2015, 40(6): 1161-1165. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY201506033.htm
    [29]
    HISADA Y, MACKMAN N. Tissue factor and cancer: regulation, tumor growth, and metastasis[J]. Semin Thromb Hemostasis, 2019, 45(4): 385-395. doi: 10.1055/s-0039-1687894
    [30]
    刘浩. 结直肠癌中TF与VEGF的表达及相关性研究[D]. 南昌: 南昌大学, 2009.
    [31]
    王学兰, 王红阳. 肺血栓栓塞患者血清中TNF-α、IL-1、IL-6、IL-8、ET-1的表达及临床意义[J]. 河北联合大学学报: 医学版, 2014, 16(2): 154-156. https://www.cnki.com.cn/Article/CJFDTOTAL-MTYX201402008.htm
    [32]
    李兴国. Racl、NF-κB、IL-1β在DVT形成中表达变化的研究[D]. 昆明: 昆明医科大学, 2012.
    [33]
    OLIVEIRA S H, CANETTI C, RIBEIRO R A, et al. Neutrophil migration induced by IL-1beta depends upon LTB4 released by macrophages and upon TNF-alpha and IL-1beta released by mast cells[J]. Inflammation, 2008, 31(1): 36-46. doi: 10.1007/s10753-007-9047-x
    [34]
    SHIRINSKY I, POLOVNIKOVA O, KALINOVSKAYA N, et al. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study[J]. Rheumatol Int, 2013, 33(12): 3045-3048. doi: 10.1007/s00296-012-2613-z
  • Related Articles

    [1]GONG Yujia, LI Hailong, CAO Hui. Mechanism of circ-001209 on retinal angiogenesis in rats with diabetic retinopathy by regulating interleukin-33/suppression of tumorigenicity 2 signaling pathway[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 23-18, 33. DOI: 10.7619/jcmp.20243144
    [2]BIAN Yun, BAI Hailong, MENG Xiaofeng, LIU Xiao, XUE Chao, LIU Ruixue, CHANG Hongkun, TIAN Fengsheng, CUI Ronggang, SU Yang, LIU mei. Analysis of network pharmacological mechanism of Zhenlian Mingmu Capsule in treatment of diabetic retinopathy[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 75-82. DOI: 10.7619/jcmp.20232153
    [3]ZUO Shufei, LIANG Shu, QIN Yilu, WU Jie, ZHANG Chao, GUO Zhanfei, BIAN Caiyue, FAN Wenqiang. Effect and mechanism of mircoRNA-6779-5p on chondrocyte injury induced by interleukin-1β[J]. Journal of Clinical Medicine in Practice, 2023, 27(12): 69-75, 79. DOI: 10.7619/jcmp.20231173
    [4]PANG Hanqing, SHANG Xiaoyu, WEI Ye, DING Shuwen, LIU Liang. Mechanism of Tongmai granules in treatment of stroke based on ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and network pharmacology[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 13-19. DOI: 10.7619/jcmp.20223482
    [5]WEI Yu, XU Xuefeng, TANG Xiaojun, LIANG Jun, FENG Xuebing, ZHAO Cheng. Role and mechanism of developmental endothelial locus-1 in collagen-induced arthritis[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 53-56. DOI: 10.7619/jcmp.20220543
    [6]LI Wenji, HU Fang, XU Wei. Mechanism of Chuanlong Anti-cancer Decoction in treatment of prostate cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 18-23. DOI: 10.7619/jcmp.20214121
    [7]JIN Xuening, LIN Fei, FENG Xinyi, LI Cen, CUI Shu′na. Mechanism of docetaxel in treatment of choriocarcinoma based on network pharmacology[J]. Journal of Clinical Medicine in Practice, 2022, 26(1): 18-21. DOI: 10.7619/jcmp.20213494
    [8]QIN Wei, YIN Zixin, HUA Weiwei, WANG Yujie, WANG Yang, DENG Jialin, CAI Zhaoying, QIAN Yayun. Mechanisms of Marsdenia tenacissima in inhibiting gastric cancer based on network pharmacologyand molecular docking technology[J]. Journal of Clinical Medicine in Practice, 2022, 26(1): 1-7,17. DOI: 10.7619/jcmp.20213297
    [9]SHEN Jing, HUANG Wenjun, NIU Lijian, MA Yongxiang, ZHANG Jing. Research on mechanism of exercise rehabilitation therapy in cardiovascular diseases[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 124-127. DOI: 10.7619/jcmp.20211454
    [10]WANG Lei, CHEN Kun. Analysis in mechanism of Taohong Siwu Decoction in the treatment of femoral head necrosis based on network pharmacology[J]. Journal of Clinical Medicine in Practice, 2021, 25(2): 10-15,19. DOI: 10.7619/jcmp.20200915
  • Cited by

    Periodical cited type(9)

    1. 张丹. 闭合性胫骨远端关节外骨折的内固定术联合抗凝药物对患者患肢功能影响. 江西医药. 2023(06): 690-692+703 .
    2. 王禹,李东光,王洪淼,刘剑,邢武军. 锁定加压钢板结合MIPPO技术治疗胫骨远端骨折的优良率及对愈合时间、负重时间、bFGF、BMP-2水平的影响. 中国医学创新. 2022(09): 139-144 .
    3. 林先禄. 切开复位内固定、MIPPO技术结合LCP钢板内固定治疗胫骨远端闭合性骨折的临床研究. 实用中西医结合临床. 2022(16): 103-106 .
    4. 景晨光,杨虎. MIPPO技术结合锁定加压钢板对A型闭合性胫骨远端骨折患者踝关节功能及活动范围的影响. 临床医学研究与实践. 2021(02): 81-83 .
    5. 陈松涛. MIPPO技术结合锁定加压钢板治疗胫骨远端骨折临床疗效分析. 微量元素与健康研究. 2021(02): 78-80 .
    6. 李涛. 两种内固定对AO分型43-A型胫骨骨折的治疗效果评价. 中国卫生标准管理. 2021(17): 52-55 .
    7. 郑义海,向明,汪爱兰,江有华,袁梦龙. 无X线透视下微创切口+内侧经皮锁定钢板治疗胫骨下段螺旋型骨折的临床效果. 医学信息. 2021(23): 69-72 .
    8. 万春根,殷伟根,奚伟伟. 外侧锁定加压钢板治疗闭合性胫骨下端骨折的效果. 医学信息. 2020(08): 133-134 .
    9. 高世龙. 经皮微创锁定加压钢板内固定术治疗胫骨远端骨折患者的有效性及安全性分析. 当代医学. 2020(20): 52-55 .

    Other cited types(1)

Catalog

    Article views (389) PDF downloads (8) Cited by(10)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return